GoodRX, Weight Watchers, LifeMD Offering Novo Nordisk's New Weight-Loss Pill

Dow Jones

01/05

By Connor Hart

GoodRX, Weight Watchers and LifeMD all said they will offer Novo Nordisk's new weight-loss pill, Wegovy, on their respective platforms.

U.S. regulators approved the new pill last month. At that time, Novo Nordisk said it planned to start selling the pill in the U.S. in early January, with a cash price of $149 a month for the starting dose.

Drug companies and analysts have said the pills will tap in to demand from people who don't want an injection or would prefer the cadence of a daily dose. Pills also offer the prospect of lower prices and better health-insurance coverage than injections, because pills cost less to make, The Wall Street Journal previously reported.

GoodRX, Weight Watchers and LifeMD all expanded their partnerships with Novo Nordisk to offer the new weight-loss pill through their respective platforms, a push to further expand access to popular GLP-1 treatments.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

January 05, 2026 08:42 ET (13:42 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2601788497"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601788497\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601788497?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-05 21:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601788497","market":"sh","top_or_hot":-1,"title":"GoodRX, Weight Watchers, LifeMD Offering Novo Nordisk's New Weight-Loss Pill","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  GoodRX, Weight Watchers and LifeMD all said they will offer <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s new weight-loss pill, Wegovy, on their respective platforms. \n</p>\n<p>\n  U.S. regulators approved the new pill last month. At that time, Novo Nordisk said it planned to start selling the pill in the U.S. in early January, with a cash price of $149 a month for the starting dose. \n</p>\n<p>\n  Drug companies and analysts have said the pills will tap in to demand from people who don't want an injection or would prefer the cadence of a daily dose. Pills also offer the prospect of lower prices and better health-insurance coverage than injections, because pills cost less to make, The Wall Street Journal previously reported. \n</p>\n<p>\n  GoodRX, Weight Watchers and LifeMD all expanded their partnerships with Novo Nordisk to offer the new weight-loss pill through their respective platforms, a push to further expand access to popular GLP-1 treatments. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 05, 2026 08:42 ET (13:42 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GoodRX, Weight Watchers, LifeMD Offering Novo Nordisk's New Weight-Loss Pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGoodRX, Weight Watchers, LifeMD Offering Novo Nordisk's New Weight-Loss Pill\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-01-05 21:42</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  GoodRX, Weight Watchers and LifeMD all said they will offer <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s new weight-loss pill, Wegovy, on their respective platforms. \n</p>\n<p>\n  U.S. regulators approved the new pill last month. At that time, Novo Nordisk said it planned to start selling the pill in the U.S. in early January, with a cash price of $149 a month for the starting dose. \n</p>\n<p>\n  Drug companies and analysts have said the pills will tap in to demand from people who don't want an injection or would prefer the cadence of a daily dose. Pills also offer the prospect of lower prices and better health-insurance coverage than injections, because pills cost less to make, The Wall Street Journal previously reported. \n</p>\n<p>\n  GoodRX, Weight Watchers and LifeMD all expanded their partnerships with Novo Nordisk to offer the new weight-loss pill through their respective platforms, a push to further expand access to popular GLP-1 treatments. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 05, 2026 08:42 ET (13:42 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0154236417.USD","symbol_name":"BGF US FLEXIBLE EQUITY \"A2\" ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2601788497","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601788497","pubTimestamp":1767620520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"GoodRX, Weight Watchers and LifeMD all said they will offer Novo Nordisk's new weight-loss pill, Wegovy, on their respective platforms.U.S. regulators approved the new pill last month. At that time, Novo Nordisk said it planned to start selling the pill in the U.S. in early January, with a cash price of $149 a month for the starting dose.Drug companies and analysts have said the pills will tap in to demand from people who don't want an injection or would prefer the cadence of a daily dose. Pills also offer the prospect of lower prices and better health-insurance coverage than injections, because pills cost less to make, The Wall Street Journal previously reported.GoodRX, Weight Watchers and LifeMD all expanded their partnerships with Novo Nordisk to offer the new weight-loss pill through their respective platforms, a push to further expand access to popular GLP-1 treatments.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4183":"个人用品","GDRX":"GoodRx Holdings, Inc.","BK4588":"碎股","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4585":"ETF&股票定投概念","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4532":"文艺复兴科技持仓","BK4192":"特殊消费者服务","LFMD":"LifeMD Inc.","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4599":"减肥药","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4167":"医疗保健技术","WW":"WW International, Inc.","BK4007":"制药"},"translate_title":"GoodRX、慧俪轻体、LifeMD提供诺和诺德的新型减肥药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GDRX":1.91,"WW":1.91,"LFMD":1.91},"content_text":"By Connor Hart \n\n\n \n\n\n  GoodRX, Weight Watchers and LifeMD all said they will offer Novo Nordisk's new weight-loss pill, Wegovy, on their respective platforms. \n\n\n  U.S. regulators approved the new pill last month. At that time, Novo Nordisk said it planned to start selling the pill in the U.S. in early January, with a cash price of $149 a month for the starting dose. \n\n\n  Drug companies and analysts have said the pills will tap in to demand from people who don't want an injection or would prefer the cadence of a daily dose. Pills also offer the prospect of lower prices and better health-insurance coverage than injections, because pills cost less to make, The Wall Street Journal previously reported. \n\n\n  GoodRX, Weight Watchers and LifeMD all expanded their partnerships with Novo Nordisk to offer the new weight-loss pill through their respective platforms, a push to further expand access to popular GLP-1 treatments. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 05, 2026 08:42 ET (13:42 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}